Exhibit 107
Calculation of Filing Fee Tables
Form F-1
(Form Type)
Altamira Therapeutics Ltd.
(Exact Name of Registrant as Specified in its Charter)
Not Applicable
(Translation of Registrant’s Name into English)
Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Amount Registered | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price(1)(2) | Fee Rate | Amount of Registration Fee(3) | |||||||||||||||||||||
Fees to Be Paid | Equity | Common shares, par value CHF 0.20 per share(5) | Other | $ | 9,200,000 | 0.0001102 | $ | 1,013.84 | ||||||||||||||||||||
Equity | Pre-Funded Warrants(5) | 457(g) | (4) | |||||||||||||||||||||||||
Equity | Common Shares underlying Pre-Funded Warrants(5) | 457(o) | (5) | 0.0001102 | (5) | |||||||||||||||||||||||
Total Offering Amounts | $ | 9,200,000 | $ | 1,013.84 | ||||||||||||||||||||||||
Total Fees Previously Paid | $ | 0 | ||||||||||||||||||||||||||
Total Fee Offsets | $ | 0 | ||||||||||||||||||||||||||
Net Fee Due | $ | 1,013.84 | (6) |
(1) | Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”). |
(2) | Includes common shares, if any, which may be issued on exercise of a 45-day option granted to the underwriters to cover over-allotments, if any. |
(3) | Calculated pursuant to Rule 457(o) under the Securities, based on an estimate of the proposed maximum aggregate offering price. |
(4) | No separate registration fee is payable pursuant to Rule 457(g) under the Securities Act. |
(5) | The proposed maximum aggregate offering price of the common shares will be reduced on a dollar-for-dollar basis based on the offering price of any Pre-Funded Warrants issued in the offering, and the proposed maximum aggregate offering price of the Pre-Funded Warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any common shares issued in the offering. Accordingly, the proposed maximum aggregate offering price of the common shares and Pre-Funded Warrants (including the common shares issuable upon exercise of the Pre-Funded Warrants), if any, is $9,200,000 (including the underwriters’ option to purchase additional common shares and/or Pre-Funded Warrants). |
(6) | Previously paid. |